Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

GRNOPC1

Cell therapy (Stem-cell derived) · Cell replacement · developed by Lineage Cell Therapeutics

Phase 1 Most advanced trial (none active)

LCTX Developer

1 Registered trials

What is GRNOPC1?

GRNOPC1 is a cell therapy consisting of oligodendrocyte progenitor cells derived from human embryonic stem cells. It is administered as a single injection of 2 million cells and is being studied for spinal cord injury.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (Stem-cell derived)
Mechanism: Cell replacement
Therapy area: Neurology
Developer: Lineage Cell Therapeutics, Inc. (LCTX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01217008	Phase 1	Spinal Cord Injury	Completed	LCTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Spinal Cord Injury

More from Lineage Cell Therapeutics

AST-OPC1 Phase 1/2

Sources

ClinicalTrials.gov NCT01217008

Updated Oct 3, 2026. Something wrong or missing? Report it on the LCTX page.

Follow LCTX, the company behind GRNOPC1

See LCTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LCTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z